5 Key Takeaways
-
1
Oculis is developing licaminlimab, a TNF-α inhibitor, for TNFR1-mediated dry eye disease.
-
2
The phase 3 PREDICT-1 trial is evaluating licaminlimab using a genotype-based development approach.
-
3
PREDICT-1 includes patients who test positive for a specified TNFR1 genetic variant.
-
4
Approximately two-thirds of PREDICT-1 participants are expected to have the specified TNFR1 genotype.
-
5
Topline results from PREDICT-1 are expected around year-end.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.